Miller, M. Et Al. 2022. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. EXPERT REVIEW OF CARDIOVASCULAR THERAPY , vol.20, no.8 , 609-625.

Miller, M., Tokgozoglu, L., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., ... Brinton, E. A.(2022). Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. EXPERT REVIEW OF CARDIOVASCULAR THERAPY , vol.20, no.8, 609-625.

Miller, Michael Et Al. "Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements," EXPERT REVIEW OF CARDIOVASCULAR THERAPY , vol.20, no.8, 609-625, 2022

Miller, Michael Et Al. "Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements." EXPERT REVIEW OF CARDIOVASCULAR THERAPY , vol.20, no.8, pp.609-625, 2022

Miller, M. Et Al. (2022) . "Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements." EXPERT REVIEW OF CARDIOVASCULAR THERAPY , vol.20, no.8, pp.609-625.

@article{article, author={Michael Miller Et Al. }, title={Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements}, journal={EXPERT REVIEW OF CARDIOVASCULAR THERAPY}, year=2022, pages={609-625} }